pp-071.1 Tablets

Indication: Advanced or metastatic non-small cell lung cancer harboring EGFR mutations, including patients who have developed resistance to earlier-generation EGFR TKIs (e.g., C797S and other acquired mutations). Clinical stage: Phase I/II clinical development. Modality: Small molecule (oral) Mechanism / Target: Mutant-selective EGFR tyrosine kinase inhibitor designed to inhibit a broad spectrum of activating and resistance EGFR mutations while sparing wild-type EGFR. Route / form: Oral tablets Differentiation: Fourth-generation EGFR inhibitor engineered to overcome key resistance mechanisms (including C797S), with selective inhibition expected to improve tolerability; aims to address unmet need in patients who progress after osimertinib and other standard EGFR-TKI therapies.